The CAPRA poster diagrams show that 2 patients already have 100% improvement, presumably they are not classified as complete response (CR) until the next assessment when hopefully it their 100% improvement will be confirmed.
And looking at the spider plot, so far every patient (bar one*) is remaining stable or improving every single time they are assessed after the first assessment at 50 days. This is spectacularly good news for durability of response.
* The one exception had their Keytruda held at day 50 because of grade 2 sinusitis, after which their disease progressed quickly. However, you can see from the spider plot that even this patient had improved slightly in that first 50 days.
I'm excited!!! This is phenomenal and seems to confirm the results in humans are quite consistent with those seen in mice. This could easily see Merck get out the cheque book. Just a case of when and how much. There's no way they want anybody else owning and controlling this one.
VLA Price at posting:
$1.20 Sentiment: Hold Disclosure: Held
